sion of tumor-associated genes was not significantly increased. Only hESC-OS at primary and first passages formed teratomas after 4 weeks in vivo. The hESC-OS were not able to revert to hESCs. Conclusions: Expanded hESC-OS demonstrated lineage-specific differentiation stability, did not maintain the pluripotency of hES cells, and were genetically stable. Thus, hESC-OS may be considered for large animal preclinical studies.
Introduction
To generate the number of osteogenic cells derived from human embryonic stem cells (hESCs) required for cell-based regeneration, a number of challenges must be overcome. Among these challenges is the necessity to hESC-OS osteoblast-like cells derived from hESCs in osteogenic medium hESCs human embryonic stem cells hMSCs human mesenchymal stem cells qRT-PCR quantitative real-time reverse transcriptase polymerase chain reaction Phenotypic and Differentiation Stability Cells Tissues Organs 2011; 194:326-330 327 prolong the expansion of the differentiated cells before transplantation and to ensure transplantation of homogenous and lineage-restricted cells. Long-term in vitro cultures of human mesenchymal stem cells (hMSCs) and osteoprogenitor cells are associated with reduced proliferative and differentiation potential due to cellular senescence [Bruder et al., 1997; Kim et al., 2009] . Furthermore, some reports have indicated that long-term culture may cause a spontaneous transformation of hMSCs [Rubio et al., 2005; Rosland et al., 2009] . This transformation potential is amplified when the differentiated cells are derived from pluripotent cells such as hES cells that are known to have a high capacity to form teratomas in vivo [Takahashi and Yamanaka, 2006] . Therefore, to ensure the efficiency and safety of hESCderived osteoblast-like cells (hESC-OS), the goals of this study were: (1) to determine the effects of continuous cell expansion on osteoblastic differentiation stability and (2) to examine the pluripotency and tumorigenic potential of long-term expanded hESC-OS.
Materials and Methods

Human Embryonic Stem Cell Culture and Osteogenic Induction
Undifferentiated hESCs (BG01; Bresagen, Inc., USA) (passages 35-50) as (1) a suspension of single cells or (2) cell aggregates were regularly passaged in osteogenic medium as described [Arpornmaeklong et al., 2010] . A karyotype analysis was performed by cytogenetic analysis on 20 G-banded metaphase cells of hESCs-OS at passages 5, 10, 17, and 20 (Cell Line Genetics, USA).
Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction
Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) was performed on hESCs and hESC-OS at the primary passage and every 5 passages thereafter as described [Arpornmaeklong et al., 2010] . The genes and primers used are listed in table 1 .
Reversion of Differentiation
hESC-OS at passages 1, 5, and 10 were seeded in 6-well culture plates (5 ! 10 3 cells/cm 2 ) and incubated for 21 days in hESC medium, human fetal fibroblast condition medium (Stemcell Technologies, Canada) on a Matrigel-(BD Biosciences, USA) coated surface for hESC culture, and osteogenic mediums (as described in the previous section) on a cell culture plate surface for differentiation culture. Cell morphology and undifferentiated cell colony formation were observed at the time of cell culture change. On day 21, hESC-OS were collected for expression of pluripotency related genes Oct4, Nanog, Sox2, and Lin28 ( table 1 ) using qRT-PCR analysis [Takahashi and Yamanaka, 2006] .
Preparation of Composite Scaffolds and Subcutaneous Transplantation
All procedures were approved by the University of Michigan Committee on the Use and Care of Animals. On culture days 6 and 7, undifferentiated hESCs (BGO1) at passages 50-60 were dissociated and hESC-OS at passages 1, 5, 10, 15, 20, and 25 were trypsinized. Cell-(2 ! 10 6 cells/pellet) gelatin sponge-(7 ! 3 mm; Pharmacia & Upjohn Co., USA) fibrin gel [40 mg/ml fibrinogen with 200 units/ml human thrombin (Sigma, USA)] composite scaffolds were prepared as described [Arpornmaeklong et al., 2010] . Six composite scaffolds were prepared for the transplantation of hESCs at passages 50-60 and hESC-OS at passage 1. A total of 18 composite scaffolds were prepared for the transplantation of dissociates and aggregates of hESC-OS at passages 5-25. Composite scaffolds were subcutaneously transplanted in 30 immunocompromised mice (N:NIHbg-nu-xid; Harlan Laboratories, Inc., Indianapolis, Ind., USA), with 4 pockets in 1 mouse and 1 sample in 1 pocket. Each pocket on 1 animal contained a composite scaffold with cells from different passages. The transplants were harvested 4, 12, and 24 weeks after transplantation. Histological sections were examined for tumor formation [Takahashi and Yamanaka, 2006] .
Statistical Analysis
Results were derived from 3 strains each of hESCs cultured as dissociated cells and cell aggregates. Data were analyzed by 1-way analysis of variance (ANOVA) at p ! 0.05. 
Results and Discussion
The decrease in osteoblastic differentiation potential after the extensive expansion of hESC-OS in vitro ( fig. 1 ac) is similar to those of osteoblast-like cells derived from hBMSCs [Bruder et al., 1997] and hMSCs [Kim et al., 2009] in aging or presenescent stages.
Tumorigenic transformation of the differentiated cells is another major concern for safe clinical application when using differentiated cells derived from stem cells. Transformed mesenchymal stem cells have a significantly increased proliferation rate, altered morphology and phenotype, and form tumors in vivo [Rubio et al., 2005; Rosland et al., 2009 ]. In the current study, the phenotypic and genotypic stability of hESC-OS in long-term expansion was indicated by the consistent absence of chromosomal abnormalities of hESC-OS at passages 5-25 revealed by normal karyotypes (data not shown), decreased hESC-OS showed osteogenic differentiation potential and genotypic stability by exhibiting an absence of spontaneous tumorigenic differentiation. Expression profiles of osteoblast-related genes (n = 3) ( a-c ) and oncogenes ( d-f ) over 20 cell passages in osteogenic medium (n = 3). g-i Decrease in the expression levels of pluripotency regulator genes at passages 5 and 10 following a reverse differentiation study (n = 6). g Oct4. h Nanog. i Sox2. * = Significant differences between groups at the same passages; ‡ = lower levels than passage 10; ++ = significantly lower levels than the primary passage (passage 0); + = highest expression levels (mean 8 SEM, p ! 0.05). expression levels of oncogenes ( fig. 1 d-f) , the lack of dedifferentiation ( fig. 1 g-i) , and the absence of tumor formation after long-term transplantation ( fig. 2 ) . Moreover, an absence of undifferentiated colonies in the reversionof-differentiation study further supported a lack of pluripotent cells and lack of undifferentiated cells in the hESC-OS (data not show) [Takahashi and Yamanaka, 2006] . The absence of tumor formation from long-term transplantation of expanded hESC-OS up to passage 25 further substantiated genomic stability and the absence of undifferentiated cells in the expanded hESC-OS pop ulation. Solid tumor and cystic lesion formation were found 4-6 weeks after transplantation in all samples of hESCs ( fig. 2 a-c) and hESC-OS at passage 1, respectively ( fig.  2 d-f ). All expanded hESC-OS at passages 5 and higher (10, 15, 20 and 25) did not form teratomas even after 6 months in vivo. Sixth months after implantation, the transplants were extensively resorbed and residual scaffolds were infiltrated with connective tissue ( fig. 2 g-i) .
Phenotypic and Differentiation Stability
Despite these findings, the alloimmunogenic reaction and integration of differentiated cells into a local environment and continuous growth and function as differentiated cells are the principle challenges requiring further studies before hESC-OS can be used for clinical applications [Motaln et al., 2010] .
Taken together, expanded hESC-OS acted as normal somatic tissue with a limited life span. Our data suggest that the application of hESC-OS at passages 5-10 should be used for developmental studies and transplantation . The current study supports the safe use of hESC-OS in in vivo applications and thus hESC-OS may be considered for large animal preclinical studies.
